oncolytic viruses

AstraZeneca scraps pact with Riva-led Transgene in further blow to oncolytic viruses
AstraZeneca scraps pact with Riva-led Transgene in further blow to oncolytic viruses
Fierce Biotech
AstraZeneca
oncolytic viruses
Transgene
Flag link:
Oncolytic virus startup TILT raises €22M to advance cancer therapies
Oncolytic virus startup TILT raises €22M to advance cancer therapies
Endpoints
TILT Biotherapeutics
oncolytic viruses
clinical trials
cancer
oncology
Flag link:
In cash saving mode, Oncorus cuts trial, staff, lease, and pipeline
In cash saving mode, Oncorus cuts trial, staff, lease, and pipeline
Endpoints
Oncorus
ONCR-177
layoffs
oncolytic viruses
Flag link:
VacV exits stealth with systemic oncolytic viral delivery tech and vision of immune system stimulation
VacV exits stealth with systemic oncolytic viral delivery tech and vision of immune system stimulation
Fierce Pharma
VacV Biotherapeutics
Vaccinia
oncolytic viruses
venture capital
Flag link:
Oncolytic virus experts at Replimune reload with $200M loan as biotech collects clinical data
Oncolytic virus experts at Replimune reload with $200M loan as biotech collects clinical data
Endpoints
Replimune
oncolytic viruses
Flag link:
Friendly fire: Using viruses to kill tumors and fight breast cancer
Friendly fire: Using viruses to kill tumors and fight breast cancer
MedCity News
oncolytic viruses
tumors
cancer
Flag link:
Replimune heads for the liver
Replimune heads for the liver
EP Vantage
Replimune
oncolytic viruses
skin cancer
Flag link:
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
BioSpace
funding
biotech
IconOVir Bio
oncolytic viruses
cancer
oncology
Aro Biotherapeutics
RNA
Flag link:
C4's Andrew Hirsch blows up IPO to $182M, while oncolytic virus upstart nabs $87M offering
C4's Andrew Hirsch blows up IPO to $182M, while oncolytic virus upstart nabs $87M offering
Endpoints
C4 Therapeutics
Oncorus
IPOs
oncolytic viruses
Flag link:
Oncorus raises $80M for 2-front oncolytic virus R&D push
Oncorus raises $80M for 2-front oncolytic virus R&D push
Fierce Biotech
Oncorus
oncolytic viruses
Flag link:
Sillajen explains Pexa-Vec trial failure – it was the rescue meds
Sillajen explains Pexa-Vec trial failure – it was the rescue meds
Pharmaforum
SillaJen
oncolytic viruses
Pexa-Vec
Flag link:
SillaJen, Transgene fall with latest oncolytic virus setback
SillaJen, Transgene fall with latest oncolytic virus setback
BioCentury
Transgene
SillaJen
clinical trials
Pexa-Vec
oncolytic viruses
Flag link:
Oncolytic virus play OncoMyx raises $25M series A
Oncolytic virus play OncoMyx raises $25M series A
BioCentury
OncoMyx
oncolytic viruses
Flag link:
AstraZeneca ups oncolytic virus activity with Transgene deal
AstraZeneca ups oncolytic virus activity with Transgene deal
Fierce Biotech
AstraZeneca
Transgene
oncolytic viruses
drug development
Flag link:
J&J’s Janssen acquires cancer-killing virus tech
J&J’s Janssen acquires cancer-killing virus tech
Drug Delivery Business News
JNJ
Janssen
BeneVir
oncolytic viruses
Flag link: